Fibroblast growth factor signalling in osteoarthritis and cartilage repair

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome

JAMA Dermatol.

Zhang A, Duchatelet S, Lakdawala N, Tower RL, Diamond C, Marathe K, Hill I, Richard G, Diab Y, Kirkorian AY, Watanabe F, Siegel DH, Hovnanian A

doi: 10.1001/jamadermatol.2019.4141.

Rheumatoid Arthritis

Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis.

Clin Exp Med.

Tong S, Liu J, Zhang C

doi: 10.1007/s10238-017-0449-2.

Osteoarthritis

Modern-day environmental factors in the pathogenesis of osteoarthritis

Nat Rev Rheumatol.

Berenbaum F, Wallace IJ, Lieberman DE, Felson DT

doi: 10.1038/s41584-018-0073-x.

Osteoarthritis

Occupation, Physical Workload Factors, and Disability Retirement as a Result of Hip Osteoarthritis in Finland, 2005-2013

J Rheumatol.

Solovieva S, Kontio T, Viikari-Juntura E

doi: 10.3899/jrheum.170748.

Osteoarthritis

Type II diabetes mellitus and incident osteoarthritis of the hand: a population-based case-control analysis

Osteoarthritis Cartilage.

Frey N, Hügle T, Jick SS, Meier CR, Spoendlin J

doi: 10.1016/j.joca.2016.04.005.

Osteoarthritis

The Molecular Profile of Synovial Fluid Changes upon Joint Distraction and is Associated with Clinical Response in Knee Osteoarthritis

Osteoarthritis Cartilage.

Watt FE, Hamid B, Garriga C, Judge A, Hrusecka R, Custers RJH, Jansen MP, Lafeber FP, Mastbergen SC, Vincent TL

doi: 10.1016/j.joca.2019.12.005.

Osteoarthritis

Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial

JAMA.

Hochberg MC, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P, Reinstrup Bihlet A, Byrjalsen I, Ragnar Andersen J, Eckstein F

doi: 10.1001/jama.2019.14735.

Osteoarthritis

Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions: A Randomized Clinical Trial

JAMA.

Cai G, Aitken D, Laslett LL, Pelletier JP, Martel-Pelletier J, Hill C, March L, Wluka AE, Wang Y, Antony B, Blizzard L, Winzenberg T, Cicuttini F, Jones G

doi: 10.1001/jama.2020.2938.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations

JAMA Dermatol.

Greco C, Leclerc-Mercier S, Chaumon S, Doz F, Hadj-Rabia S, Molina T, Boucheix C, Bodemer C

doi: 10.1001/jamadermatol.2019.4126.

Related content

Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome

Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis.

Modern-day environmental factors in the pathogenesis of osteoarthritis

Occupation, Physical Workload Factors, and Disability Retirement as a Result of Hip Osteoarthritis in Finland, 2005-2013

Type II diabetes mellitus and incident osteoarthritis of the hand: a population-based case-control analysis

The Molecular Profile of Synovial Fluid Changes upon Joint Distraction and is Associated with Clinical Response in Knee Osteoarthritis

Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial

Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions: A Randomized Clinical Trial

Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations